Reports

Broadcom delivered strong Q1 FY2026 results with revenue increasing 29% year-over-year to $19311000000. Net income reached $7349000000 and operating income totaled $8563000000 as demand for AI semiconductor solutions accelerated and drove significant profitability and cash generation.

• Revenue increased 29% year-over-year to $19311000000.
• AI semiconductor revenue reached $8400000000 with strong demand for custom accelerators and networking.

Veeva reported Q4 FY2026 revenue of $835951000, up 16% year-over-year, driven by continued growth in subscription services. Profitability expanded significantly with operating income rising to $245876000 and net income reaching $244204000, reflecting strong margin expansion and operating leverage.

• Total Q4 revenue grew 16% year-over-year to $835951000.
• Subscription revenue reached $707745000, continuing to dominate the revenue mix.

BBVA Argentina generated ARS 59.3 billion in net income in Q4 2025, supported by higher net interest income and disciplined cost control. Sequential results improved despite rising loan loss provisions and continued pressure in the retail credit portfolio. The bank maintained solid liquidity and capital levels while continuing loan and deposit growth.

• Net income reached ARS 59.3 billion in Q4 2025, increasing 44.5% quarter-over-quarter.
• Net interest income totaled ARS 758.9 billion driven by higher yields and stabilization of interest rates.

Brown-Forman delivered a 2% increase in quarterly net sales driven by innovation and growth in emerging markets and travel retail, while operating income rose sharply due to lower restructuring costs and operating efficiencies. Net income remained relatively stable year over year as improved margins offset cost pressures and portfolio changes.

• Net sales increased 2% year-over-year to 1056000000.
• Operating income rose 21% to 340000000 with margin expansion.

Okta delivered solid Q4 FY2026 results with revenue growing 11% year-over-year to $761 million while profitability improved materially, with GAAP operating income rising to $46 million and net income reaching $63 million. The company also generated strong operating cash flow and free cash flow during the quarter.

• Revenue grew 11% year-over-year to $761 million driven primarily by subscription revenue.
• GAAP operating income expanded to $46 million compared with $8 million in the prior year quarter.

Dycom reported record fourth-quarter revenue driven by strong demand for fiber and digital infrastructure services and the addition of the Power Solutions acquisition. While GAAP net income declined due to acquisition-related costs, adjusted earnings and EBITDA increased significantly and backlog reached record levels.

• Revenue increased 34.4% year-over-year to $1457562000 in Q4 2026.
• Adjusted diluted EPS rose to $2.03 from $1.43 in the prior-year quarter.

Rigetti generated $1.87 million in Q4 2025 revenue while continuing to operate at a significant loss as it invests in quantum technology development. The company reported a GAAP net loss of $18.21 million and an operating loss of $22.60 million, while maintaining a strong balance sheet with nearly $589.8 million in cash and investments.

• Q4 revenue totaled $1868000 compared with $2274000 in the prior year quarter.
• Operating loss reached $22597000 as R&D and infrastructure investments remained high.

Bath & Body Works generated fourth quarter net sales of 2724000000, down slightly from the prior year, while net income declined to 403000000 and operating income decreased to 599000000. Despite the year-over-year decline, the company exceeded its internal guidance and continued executing strategic initiatives focused on brand modernization, innovation, and distribution expansion.

• Fourth quarter revenue declined slightly year over year to 2724000000.
• Net income was 403000000 compared with 453000000 in the prior year period.

Stevanato Group delivered solid fourth-quarter performance with revenue growth driven by its Biopharmaceutical and Diagnostic Solutions segment and strong demand for high-value solutions. Profitability improved with higher gross margins and expanded adjusted EBITDA margins despite a decline in the Engineering segment.

• Revenue increased 5% year-over-year to €346.5 million in Q4 2025.
• High-value solutions revenue grew 31% year-over-year, reaching €171.4 million and representing 49% of total revenue.

Abercrombie & Fitch delivered record Q4 net sales of $1.67 billion, representing 5% growth, though operating margins compressed to 14.1% from 16.2% in the prior year. The company achieved its thirteenth consecutive quarter of growth and significantly reduced its share count through $450 million in repurchases during the full fiscal year.

• Record fourth quarter net sales of $1.67 billion, up 5% year-over-year.
• Hollister brand family led growth in Q4 with a 6% increase in net sales and 3% comparable sales growth.

Wix delivered strong top-line performance in Q4 2025 with revenue growing 14% year over year to $524.27 million and bookings rising 15%. Growth was driven by momentum in new cohorts and continued expansion in Business Solutions. Despite strong free cash flow generation and improving ARR, the company reported a GAAP net loss due to elevated operating expenses and acquisition-related costs tied to strategic investments.

• Revenue grew 14% year over year to $524.27 million with continued strength in Business Solutions.
• Total bookings increased 15% year over year to $534.52 million, reflecting strong cohort performance.

PagBank delivered solid Q4 2025 results characterized by strong banking growth and disciplined repricing in the payments segment. While GAAP net income was impacted by a one-time deferred tax recognition, non-GAAP profitability remained robust with a 7.4% increase in net income. The company continues to shift its mix toward banking services and higher-yield credit products while executing a significant share buyback program.

• Banking revenue grew 47.4% year-over-year, now representing 21% of total revenue excluding interchange fees.
• The credit portfolio expanded by 32.8% year-over-year to R$4.6 billion, driven by a 170% surge in working capital loans.

American Eagle Outfitters delivered a record fourth quarter with a 10% revenue increase and strong comparable sales growth of 8%. Performance was led by Aerie's 23% comp growth and a return to positive growth for the American Eagle brand. Despite a $50 million tariff impact, the company achieved significant adjusted operating margin expansion through cost efficiencies and SG&A leverage.

• Total revenue reached a record $1.8 billion for the quarter, up 10% year-over-year.
• Aerie continued its high-growth trajectory with a 23% increase in comparable sales.

BillionToOne delivered a strong fourth quarter with 113% revenue growth and a successful transition to GAAP profitability. The company saw significant expansion in its oncology segment and improved gross margins to 71%, leading to a raise in its full-year 2026 revenue guidance.

• Total revenue grew 113% year-over-year to $96.1 million, driven by volume growth and higher ASP.
• Achieved GAAP operating income of $10.3 million, compared to an $11.7 million loss in the prior year period.

StubHub generated $449173000 in Q4 2025 revenue with Gross Merchandise Sales of $2300000000. The company reported a GAAP net loss of $535313000, largely driven by a $479000000 non-recurring non-cash valuation allowance expense, while adjusted EBITDA remained positive at $62655000.

• Revenue totaled $449173000 in Q4 2025 compared with $533415000 in the prior year quarter.
• Net loss was $535313000 primarily due to a $479000000 non-cash valuation allowance expense.

Webull generated $165198822 in Q4 2025 revenue, a 50% year-over-year increase driven by strong growth in equities and options trading. Net income totaled $3041326, declining from the prior year as marketing and product expansion spending increased while the platform continued to scale globally.

• Total Q4 revenue grew 50% year-over-year to $165198822 driven by higher trading activity.
• Net income attributable to the company totaled $3041326 compared with $10761985 in the prior year quarter.

National Vision delivered strong fourth quarter results with net revenue increasing 15.1% year over year to $503.4 million, supported by comparable store sales growth and new store openings. The company returned to profitability with net income of $3.3 million and improved operating margins, while adjusted operating income rose significantly reflecting strong cost discipline and operating leverage.

• Net revenue increased 15.1% year over year to $503.4 million driven by comparable store sales growth and new stores.
• Comparable store sales grew 6.6%, marking the twelfth consecutive quarter of positive comparable growth.

Vermilion achieved record annual production of 119,919 boe/d in 2025, driven by the integration of the Westbrick acquisition. The company focused on debt reduction, successfully reducing net debt by approximately $720 million since the Westbrick closing. Despite a volatile commodity price environment, Vermilion maintained a disciplined capital program and increased its quarterly dividend for the upcoming 2026 period.

• Achieved record annual production of 119,919 boe/d in 2025.
• Reduced net debt by approximately $720 million through Q4 2025.

Genius Sports delivered a strong fourth quarter with revenue growing 37% year-over-year to $240.5 million, driven by massive growth in the Media segment. While the company remains net loss-making, it showed a year-over-year improvement in net loss and a 49% increase in Adjusted EBITDA, signaling improved operational efficiency and scale.

• Group Revenue increased 37% year-over-year to $240.5 million in Q4.
• Media Technology, Content & Services revenue surged 96% due to new programmatic advertising partnerships.

Daktronics delivered strong third-quarter results with a 21.6% increase in sales and a return to profitability, reporting net income of $3.0 million compared to a significant loss in the prior year. Growth was driven by efficient backlog fulfillment and strong performance in the Live Events and Commercial segments, while the company also secured a new $71.5 million credit facility to enhance financial flexibility.

• Sales grew 21.6% year-over-year to $181.9 million, driven by efficient fulfillment of existing backlog.
• Product backlog reached $342.3 million, a 25.3% increase compared to the end of Q3 fiscal 2025.

Amprius generated $25234000 in revenue in Q4 2025, up significantly year over year as customer demand increased and commercial traction improved. Gross profit reached $5967000 with a GAAP gross margin of 24%, while the company reported a net loss of $24391000 primarily due to a $22524000 impairment charge related to the Brighton, Colorado facility. Excluding the charge, adjusted net loss was significantly lower and adjusted EBITDA turned positive.

• Revenue rose to $25234000, representing 137% year-over-year growth.
• Gross profit improved to $5967000 with gross margin reaching 24%.

Preformed Line Products generated $173109000 in net sales during Q4 2025, representing a 4% increase year-over-year. Growth was supported by strong demand in energy and communications markets and increased international sales, partially aided by foreign currency translation. However, net income declined to $8435000 due to tariff impacts and higher inventory valuation costs.

• Net sales increased 4% year-over-year to $173109000.
• Foreign currency translation increased quarterly net sales by $4400000.

EyePoint Pharmaceuticals reported a significant decrease in revenue for Q4 2025, primarily due to the exhaustion of deferred revenue from a 2023 licensing agreement. The company is heavily investing in Phase 3 clinical trials for DURAVYU in wet AMD and DME, leading to increased operating losses, but maintains a strong cash position of over $300 million to fund operations into late 2027.

• Pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD are on track for topline data readouts beginning in mid-2026.
• First patients have been dosed in the Phase 3 COMO and CAPRI clinical trials for DURAVYU in Diabetic Macular Edema (DME).

Grocery Outlet reported a significant net loss in Q4 2025 primarily due to non-cash impairment charges of $259.2 million related to long-lived assets and goodwill. Despite the bottom-line loss, net sales grew by 10.7% (aided by a 53rd week), and the company announced a major Optimization Plan to close 36 underperforming stores to improve future profitability.

• Net sales increased 10.7% to $1.22 billion, including $82.4 million from an extra 53rd week.
• Comparable store sales declined by 0.8% on a 13-week basis, impacted by delayed federal benefit disbursements.

Janus International Group reported a slight revenue decline in Q4 2025 but achieved significant growth in net income and adjusted EBITDA margins despite a challenging macroeconomic environment. The company successfully managed costs and saw strong performance in its R3 segment, while providing a positive outlook for 2026 including the integration of the Kiwi II acquisition.

• Q4 revenue decreased 1.9% year-over-year to $226.3 million, primarily driven by a 5.0% decline in Commercial and Other revenues.
• Net income rose significantly to $7.1 million compared to $0.3 million in the prior year quarter.

Babcock & Wilcox generated Q4 2025 revenue of $161000000, roughly flat year over year, while operating income increased sharply to $12200000 from $2600000 in the prior-year period. Adjusted EBITDA rose to $16400000 as the company reduced its loss from continuing operations to $3500000 and strengthened its balance sheet while securing a large data center project that boosted backlog.

• Revenue remained stable at $161000000 compared with $161800000 in Q4 2024.
• Operating income increased significantly to $12200000 from $2600000 year over year.

Vinci Compass reported a strong fourth quarter with significant growth in management fees and total assets under management, driven by the combination with Compass and the acquisition of Verde. Despite a decline in performance and advisory fees, the company achieved a substantial increase in Investment Related Earnings and maintained a healthy Adjusted Distributable Earnings margin.

• Total Assets Under Management (AUM) reached R$354.1 billion, a 6% increase year-over-year.
• Management fee revenues grew 29% year-over-year to R$219.7 million, supported by organic fundraising and inorganic expansion.

Cracker Barrel faced a challenging second quarter with total revenue declining 7.9% to $874.8 million and GAAP net income falling to $1.3 million. The company experienced broad-based sales pressure in both restaurant and retail segments, though management highlighted improvements in leading guest metrics and a disciplined focus on operational excellence.

• Total revenue decreased 7.9% year-over-year to $874.8 million, driven by lower comparable store sales.
• Comparable store restaurant sales fell 7.1%, while comparable store retail sales dropped 9.2%.

Riskified delivered a strong fourth quarter, achieving GAAP profitability for the first time with a net profit of $5.8 million. Revenue reached a record $99.3 million, up 6% year-over-year, while Adjusted EBITDA grew significantly to $17.7 million. The company also reported its highest quarterly new business total in several years and continued its aggressive share repurchase program.

• Achieved first-ever quarter of GAAP profitability with $5.8 million in net income.
• Recorded highest quarterly gross profit in company history at $56.8 million (57% margin).

SandRidge generated $39.40 million in oil, natural gas and NGL revenue during the fourth quarter of 2025, producing 19.5 MBoed and reporting net income of $21.64 million. Production increased modestly year-over-year with strong contributions from the Cherokee development program while natural gas pricing improved compared to the prior year period.

• Total revenue from oil, natural gas and NGL sales reached $39400000 in Q4 2025.
• Net income was $21643000 with basic earnings per share of $0.59.

Tiptree reported a net income of $5.9 million for Q4 2025, driven by discontinued operations as the company prepares to sell its major assets, Fortegra and Reliance First Capital. The company is shifting toward a pro-forma book value of approximately $923 million following these transactions, while continuing operations reported a loss due to the reclassification of revenue-generating segments to assets held for sale.

• Agreed to sell Fortegra for $1.65 billion, with $1.12 billion in estimated gross proceeds to Tiptree expected in mid-2026.
• Agreed to sell mortgage business Reliance First Capital for approximately $50 million, expected to close in the first half of 2026.

Riley Permian delivered a transformational fourth quarter, significantly increasing production to 35.5 MBoe/d and completing the strategic sale of its Dovetail Midstream assets for $123 million. The company utilized proceeds to reduce debt by $120 million, ending the year with a strong 1.0x leverage ratio while initiating a $100 million share repurchase program.

• Achieved record average production of 35.5 MBoe/d, a 42% increase compared to the prior year period.
• Successfully divested Dovetail Midstream LLC for $123 million in cash, resulting in a $72 million pre-tax gain.

SES AI achieved significant revenue growth in 2025, reaching $21 million for the full year, driven by EV service agreements and the acquisition of UZ Energy. While Q4 gross margins were impacted by a shift toward lower-margin ESS hardware, the company maintained a strong liquidity position of $200 million and is pivoting toward high-growth sectors including drones and AI-driven material discovery.

• Full year 2025 revenue grew nearly 10-fold to $21 million, meeting the company's guidance range.
• The company is transitioning its South Korea facility to manufacture NDAA-compliant drone cells to capture the US defense market.

Bowman generated $128964000 in gross contract revenue during the fourth quarter of 2025, with net service billing of $114648000 and adjusted EBITDA of $19865000. Despite higher revenue and improved EBITDA, net income declined to $1966000 due to higher operating costs and interest expenses.

• Gross contract revenue reached $128964000, increasing 14.0% year-over-year.
• Net service billing totaled $114648000, up 16.2% compared with the prior year.

Enhabit generated $270400000 in net service revenue in Q4 2025, supported by growth in both home health and hospice segments. Adjusted EBITDA increased to $28000000, while the company reported a net loss of $38700000 primarily due to goodwill impairment charges.

• Total net service revenue increased to $270400000 with growth across home health and hospice segments.
• Adjusted EBITDA reached $28000000 with a margin of 10.4%.

Holley Performance Brands reported a strong fourth quarter with net sales growth of 10.9% and a significant return to profitability, recording net income of $6.3 million compared to a substantial loss in the prior year. The company exceeded top-line expectations for the full year and successfully reduced its leverage ratio to 3.75x.

• Net sales for Q4 increased 10.9% year-over-year to $155.4 million.
• Core business net sales grew by 13.5% in Q4 after excluding divested and non-core operations.

Miller Industries experienced a significant decline in revenue and net income during the fourth quarter of 2025 as distributor inventories normalized. Despite the top-line pressure, the company improved its gross margin slightly and continued strategic expansions, including the acquisition of Omars and a major capacity expansion in Ooltewah to support future military and international demand.

• Revenue decreased 22.9% year-over-year to $171.2 million as distributor inventory levels returned to historical averages.
• Net income fell 67.6% to $3.4 million, primarily driven by lower sales volumes and a 7.1% increase in SG&A expenses.

Aquestive saw revenue growth driven by its manufacturing business, though net losses widened significantly due to one-time legal settlement costs and increased pre-commercial spending for Anaphylm. The company is focused on resubmitting its Anaphylm NDA in Q3 2026 following a Type A meeting with the FDA.

• Total revenue increased 10% year-over-year to $13.0 million, primarily driven by manufacture and supply growth.
• Received an FDA Complete Response Letter for Anaphylm in January 2026; resubmission is targeted for Q3 2026.

Mistras delivered a strong Q4 2025 with revenue growing 5.1% to $181.5 million and record Adjusted EBITDA of $24.8 million. Despite a decrease in GAAP net income due to reorganization costs, the company expanded its gross margin by 190 basis points and saw growth across all operating segments.

• Achieved record fourth quarter Adjusted EBITDA of $24.8 million, an 18.2% increase year-over-year.
• Gross profit margin expanded by 190 basis points to 28.4% in the fourth quarter.

Ocugen reported negative revenue for the fourth quarter driven by adjustments in collaborative arrangement revenue and posted a net loss as R&D spending increased to support clinical development programs. The company continued advancing multiple gene therapy candidates and ended the quarter with limited cash, supplemented by financing in early 2026 to extend its runway.

• Negative collaborative arrangement revenue resulted in total Q4 revenue of -$193K.
• Net loss widened to $17.71M as operating expenses increased year over year.

Intrepid Potash reported a strong fourth quarter and full year 2025, driven by record Trio® sales volumes and improving fertilizer pricing. While the company saw a slight net loss in Q4 due to legal and disposal charges, adjusted EBITDA and net income showed significant year-over-year growth, supported by improved unit economics and robust demand.

• Record Trio® sales volumes of 303 thousand tons for the full year 2025, with Q4 sales increasing 84% year-over-year.
• Adjusted EBITDA for Q4 2025 rose to $18.1 million, more than doubling the $8.6 million reported in Q4 2024.

Verastem Oncology reported a transformative fourth quarter driven by the commercial launch of AVMAPKI FAKZYNJA CO-PACK, which generated $17.5 million in net product revenue. While operating expenses increased significantly due to commercialization and R&D activities, the company strengthened its balance sheet through a public offering and warrant exercises, extending its cash runway into the first half of 2027.

• AVMAPKI FAKZYNJA CO-PACK generated $17.5 million in net product revenue for Q4 2025 following its May 2025 FDA approval.
• The company reported a GAAP net loss of $32.9 million for the quarter, an improvement from the $64.6 million loss in the prior year period.

ATN generated $184216000 in revenue in Q4 2025, up 2% year-over-year, supported by growth in international and US telecom operations. Operating income improved significantly to $15703000, while adjusted EBITDA increased to $49976000. Despite stronger operating performance, the company reported a net loss of $3296000 primarily due to an equity investment write-down and higher taxes.

• Revenue increased 2% year-over-year to $184216000.
• Adjusted EBITDA grew 8% to $49976000 reflecting operational improvements.

Nexxen delivered lower fourth-quarter revenue as reduced political advertising and weaker CTV demand weighed on results. Programmatic revenue remained the dominant revenue stream, representing the vast majority of total revenue, while adjusted EBITDA declined year over year despite maintaining strong margins. The company ended the quarter with a solid cash position and no long-term debt.

• Revenue declined 10% year-over-year to 100711000 in Q4 2025.
• Programmatic revenue reached 94300000 and represented approximately 94% of total revenue.

Park-Ohio reported a 2% year-over-year revenue increase in Q4 2025, driven by growth in Supply Technologies and Assembly Components. Despite a GAAP net income decrease due to non-cash asset impairment charges in the Engineered Products segment, the company generated strong free cash flow of $36 million and significantly reduced debt. Management highlighted record bookings and a growing backlog as key drivers for expected growth in 2026.

• Revenue increased 2% year-over-year to $395 million in the fourth quarter.
• Strong free cash flow of $36 million allowed for a $40 million reduction in revolving credit facility borrowings.

Niagen Bioscience delivered a solid fourth quarter with a 16% increase in net sales, driven primarily by strong e-commerce growth for Tru Niagen®. While net income decreased compared to the prior year due to one-time benefits in 2024, the company achieved record full-year revenue and significantly strengthened its cash position and intellectual property portfolio.

• Q4 net sales grew 16% year-over-year to $33.8 million, led by a 21% increase in Tru Niagen® sales.
• Gross margin expanded by 160 basis points to 64.1% due to lower-cost inventory and improved overhead utilization.

Ooma delivered a strong fourth quarter with 15% year-over-year revenue growth and a return to GAAP profitability. The results were bolstered by the strategic acquisitions of FluentStream and Phone.com, which contributed $6.1 million in revenue, and record sales of AirDial.

• Total revenue reached $74.6 million, a 15% increase year-over-year, driven by Ooma Business growth.
• Achieved GAAP net income of $4.0 million, compared to a net loss in the prior year period.

Hudson Technologies generated $44410000 in revenue during the fourth quarter of 2025, representing a 28% increase year-over-year driven by stronger sales volume. However, the company recorded a net loss of $8633000 as gross margin declined to 8.0% due to inventory-related costs and higher operating expenses including executive severance.

• Revenue increased 28% year-over-year to $44410000 driven by stronger sales volume.
• Gross margin declined significantly to 8.0% due to inventory-related adjustments and cost pressures.

SmartRent achieved its first quarter of year-over-year revenue growth in seven quarters and reached positive Adjusted EBITDA. The company saw a significant 13% increase in SaaS revenue and expanded its total deployed base to over 890,000 units, despite a full-year revenue decline caused by the transition away from bulk hardware sales.

• Total revenue for Q4 2025 grew 3% year-over-year to $36.5 million.
• Achieved positive Adjusted EBITDA of $0.2 million, a significant improvement from a $7.4 million loss in Q4 2024.

Ring Energy generated $66.9 million in revenue during Q4 2025 but reported a net loss of $12.8 million driven primarily by a $35.9 million non-cash ceiling test impairment. Operational performance remained stable with average production of 20,508 Boe/d and lower lease operating expenses. The company continued to produce positive free cash flow and reduced debt during the quarter.

• Revenue totaled $66.9 million while the company recorded a $12.8 million net loss due largely to a $35.9 million non-cash impairment.
• Average production reached 20,508 Boe/d, exceeding the midpoint of guidance.

Sight Sciences returned to growth in its Interventional Glaucoma segment and achieved significant gross margin expansion in its Dry Eye business during Q4 2025. The company demonstrated strong fiscal discipline by reducing operating expenses by 25% and narrowing its net loss significantly compared to the prior year.

• Total revenue increased 7% year-over-year to $20.4 million, driven by growth in both business segments.
• Net loss narrowed to $4.2 million ($0.08 per share) from $11.8 million ($0.23 per share) in the prior year period.

Cross Country Healthcare reported a significant net loss in Q4 2025, primarily driven by non-cash impairment charges and tax valuation allowances following the termination of the Aya Merger Agreement. While revenue declined 24% year-over-year due to a challenging travel staffing market, the company maintained a strong debt-free balance sheet and positive operating cash flow.

• Net loss of $82.9 million was largely due to a $77.9 million goodwill and trade name impairment charge and a $29.6 million tax valuation allowance.
• The company received a $20.0 million termination fee following the cancellation of the Aya Merger Agreement.

Seaport Entertainment Group generated $29.49 million in Q4 2025 revenue, increasing 30.4% year-over-year driven by growth in hospitality and entertainment segments following the consolidation of the Tin Building operations. Despite the revenue growth, the company reported a net loss of $36.52 million and an operating loss of $35.54 million due to elevated operating costs and a loss on assets held for sale.

• Total revenue increased 30.4% year-over-year to $29.49 million driven by hospitality and entertainment growth.
• Hospitality revenue rose significantly following consolidation of Tin Building operations.

MicroVision reported a significant decline in Q4 revenue to $0.2 million and a net loss of $37.8 million, heavily impacted by $29.4 million in non-cash impairment and inventory charges. Despite the financial loss, the company is pivoting toward a commercial phase following the strategic acquisitions of assets from Luminar and Scantinel Photonics.

• Revenue decreased to $0.2 million in Q4 2025 from $1.7 million in the prior year period.
• Net loss widened to $37.8 million, driven by $29.4 million in non-cash asset impairments and inventory write-downs.

European Wax Center generated Q4 revenue of $45.1 million, down from the prior year as system-wide sales declined and same-store sales turned slightly negative. The company reported a net loss of $1.46 million while adjusted profitability also declined due to lower revenue and higher operating expenses.

• Total revenue declined 9.3% year over year to $45.1 million.
• System-wide sales decreased 1.6% to $225.6 million.

Everspin achieved a 12% year-over-year revenue increase in Q4 2025, reaching $14.8 million, driven by strong product sales in Data Center and Industrial sectors. While GAAP net income remained flat at $1.2 million, the company saw a significant increase in design wins, signaling future growth potential.

• Total revenue grew 12% year-over-year to $14.8 million in Q4 2025.
• MRAM product sales increased 22.4% year-over-year to $13.5 million.

OmniAb reported a decrease in Q4 revenue to $8.4 million, primarily due to lower license and service revenue, while net loss widened slightly to $14.2 million. Despite the financial decline, the company expanded its partner base to 107 active partners and launched OmniUltra™, a new transgenic chicken technology for antibody discovery.

• Q4 revenue decreased to $8.4 million from $10.8 million in the prior year period.
• Active partners grew to 107 with a total of 407 active programs as of year-end.

TriplePoint Venture Growth BDC Corp. generated $22.54 million in total investment and other income during Q4 2025 and reported net investment income of $9.94 million, or $0.25 per share. Net assets increased by $8.11 million during the quarter as realized gains partially offset unrealized investment losses, while the portfolio maintained a 12.7% weighted average debt yield.

• Total investment and other income reached $22541000 in Q4 2025, down from the prior year due to lower yields.
• Net investment income totaled $9938000, equal to $0.25 per share.

Alto Ingredients achieved a significant turnaround in Q4 2025, returning to profitability with a net income of $21.5 million compared to a heavy loss in the prior year. The improvement was driven by higher crush margins, 45Z tax credits, and strong renewable fuel export sales, marking a successful strategic realignment to remove structural costs.

• Returned to profitability with Q4 net income of $21.5 million, a $63.5 million improvement over Q4 2024.
• Adjusted EBITDA grew to $27.9 million, up $35.6 million year-over-year.

ChargePoint achieved $109.3 million in Q4 revenue, hitting the top end of its guidance. The company saw significant improvements in GAAP and non-GAAP gross margins driven by subscription growth, while narrowing its GAAP net loss by 24% compared to the prior year.

• Q4 revenue grew 7% year-over-year to $109.3 million, led by an 11% increase in subscription revenue.
• GAAP gross margin improved to 31% from 28% in the prior year, while non-GAAP gross margin reached 33%.

MagnaChip reported Q4 2025 revenue of $40.6 million, meeting the midpoint of its guidance, though it faced a significant year-over-year decline of 20.7%. The company is undergoing a structural transformation, including the classification of its Display business as discontinued operations and a headcount reduction program to improve its cost structure in the power semiconductor market.

• Consolidated revenue from continuing operations was $40.6 million, down 20.7% year-over-year.
• Launched 24 new-generation products in Q4, totaling 55 for the full year 2025.

Stem achieved its first-ever full year of positive Adjusted EBITDA in 2025, driven by a strategic shift toward a software-centric model. While Q4 revenue declined year-over-year due to reduced battery hardware sales, the company saw significant growth in high-margin software and services revenue and achieved positive operating cash flow for the quarter.

• Achieved first-ever full year of positive Adjusted EBITDA ($6.7 million) and positive operating cash flow ($6.9 million).
• Software, services, and edge hardware revenue grew 62% year-over-year in Q4 2025 to $46.5 million.

Altisource reported Q4 2025 service revenue of $39.9 million, a 4% increase year-over-year. While the company experienced a GAAP net loss of $7.2 million due to a $7.5 million litigation settlement, it achieved positive Adjusted EBITDA of $4.0 million and reported strong sales wins estimated to generate $13.2 million in stabilized annual revenue.

• Service revenue grew 4% year-over-year to $39.9 million in Q4 2025.
• Q4 results were impacted by a $7.5 million litigation settlement loss and related defense costs.

TScan Therapeutics generated modest collaboration revenue in the fourth quarter driven by its Amgen agreement while significantly narrowing its net loss year-over-year due to reduced operating expenses. The company continued advancing its ALLOHA Phase 1 program and strengthened its pipeline with new IND clearances targeting CD45. Cash resources are expected to fund operations into the second half of 2027.

• Revenue increased to 2567000 in Q4 2025 driven by collaboration activities with Amgen.
• Net loss narrowed to 22977000 compared with 35809000 in the prior-year quarter.

AFC Gamma reported a return to GAAP profitability in Q4 2025 with net income of $0.9 million, despite a negative distributable earnings figure of $(2.8) million. The company successfully completed its BDC conversion during the year and is focusing on redeploying capital from legacy positions into high-quality lower middle-market businesses.

• Achieved GAAP net income of $0.9 million for the fourth quarter, a recovery from the full-year net loss.
• Reported negative Distributable Earnings of $(2.8) million, or $(0.12) per share, for the quarter.

Cardlytics reported a challenging fourth quarter with a 24.2% revenue decline, primarily driven by the conclusion of major bank campaigns. Despite the revenue drop, the company improved its bottom line, achieving positive Adjusted EBITDA and positive Free Cash Flow through disciplined cost management and a reduction in net loss.

• Total Revenue decreased 24.2% year-over-year to $56.1 million.
• Adjusted EBITDA increased to $8.5 million, up from $6.4 million in the prior year despite lower billings.

SCYNEXIS strengthened its financial position in Q4 2025 by receiving $24.8 million from GSK, extending its cash runway into 2028. While the company focused on advancing its second-generation fungerp SCY-247, total cash reserves decreased year-over-year to $56.3 million.

• Received $24.8 million in non-refundable payments from GSK during the fourth quarter.
• Cash runway extended for more than two years, providing stability for clinical development.